Fluence Therapeutics Inc. - Innovative Blood-Brain Barrier Technology for Brain Drug Delivery

An Overview of Fluence Therapeutics Inc.

Fluence Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is pioneering a new approach that enables the efficient transmission of therapeutic drug doses directly to the brain using their proprietary Focused Ultrasound (FUS) technology.

The Technology Behind Fluence Therapeutics

The FUS technology developed by Fluence involves using focused ultrasound waves to temporarily disrupt the blood-brain barrier (BBB), which normally prevents large molecules from entering the brain from the bloodstream. This disruption allows therapeutic drugs to be delivered across the BBB to target tissues in the brain.

Once the drug has been transmitted, the BBB self-reseals and returns to normal function within a few hours. This approach enables significantly higher drug doses to reach neural tissues than existing methods such as oral medication or injections, leading to improved treatment outcomes.

Advantages of the FUS Platform

There are several key advantages to using Fluence's FUS technology for drug delivery to the brain:

• Non-invasive - No surgical intervention is required.
• Temporal control - The BBB disruption can be precisely timed.
• Targeted delivery - Focused ultrasound allows drugs to be transmitted to specific brain regions.
• Rapid clearance - The technology avoids residual drug buildup in the brain.
• Reversible effect - The BBB reforms within hours after treatment.

Fluence's Clinical Pipeline

Fluence Therapeutics is advancing an innovative pipeline of clinical programs using FUS to enable targeted drug delivery for treating major psychiatric and neurological conditions:

Treatment-Resistant Depression

The company's most advanced program focuses on treatment-resistant depression (TRD). Fluence is using FUS to deliver ketamine, an established antidepressant, directly to neural circuits implicated in depression and mood disorders.

Initial clinical results demonstrate that FUS-delivered ketamine leads to rapid and sustained antidepressant effects without the side effects seen with intravenous treatment. A phase 2 pivotal study is slated for initiation in 2023.

Parkinson's Disease

Fluence is also pursuing FUS delivery of the dopamine precursor levodopa for treating motor complications in Parkinsons disease patients. Preclinical studies indicate that this approach may improve motor symptoms that involve dopamine deficiency.

The treatment is currently in a phase 1 safety trial in New Zealand with plans for global expansion based on positive results. Enrollment in this study commenced in early 2023.

Other Indications

Beyond depression and movement disorders, the company envisions expanding applications of its FUS platform for targeted brain delivery of gene therapies as well as large molecules such as antibodies, proteins, and peptides.

These additional indications involving serious neurological conditions are currently being explored in preclinical studies, with a goal of advancing new clinical programs in the coming years.

Expert Team Guiding Innovation

Fluence Therapeutics was founded in 2018 by leading experts in neuroscience, clinical medicine, engineering, and drug development. The company is led by CEO Robert Langer and President Mark Milton, PhDs, both renowned innovators in biotechnology.

The management team and board of directors feature distinguished researchers from Harvard Medical School/Massachusetts General Hospital as well as pharmaceutical veterans who have successfully guided numerous novel therapies to FDA approval.

This world-class group of doctors and scientists provides the knowledge, experience, and capabilities necessary to effectively transform Fluences technology into validated medical treatments that can improve patient outcomes.

A Promising Future in Brain Therapeutics

Fluence Therapeutics represents an exciting new frontier in targeted drug delivery for treating neurological and psychiatric disorders. By non-invasively transmitting therapeutic agents past the BBB, their FUS technology platform enables delivery right to the source of these diseases - the central nervous system.

With a robust pipeline focused on areas of major unmet need like depression and Parkinsons disease, Fluence has set its sights on developing the next generation of transformative brain therapies. Initial clinical data provides convincing validation of this technology's capabilities and safety.

As research continues apace in additional indications, the application of Fluences approach may ultimately lead to superior medical outcomes for patients affected by a wide range of previously untreatable or difficult-to-treat conditions involving the brain.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.